John C Van Swieten

List of Publications by Year
in descending order

213 papers	24,511 citations	36691 53 h-index	9118 149 g-index
242 all docs	242 docs citations	242 times ranked	20485 citing authors

#	Article	IF	Citations
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	0.7	18
2	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	0.9	7
3	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 336-339.	0.9	1
4	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
5	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
6	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	1.2	3
7	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2
8	The severity of behavioural symptoms in FTD is linked to the loss of GABRQâ€expressing VENs and pyramidal neurons. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	10
9	Dataâ€driven staging of genetic frontotemporal dementia using multiâ€modal <scp>MRI</scp>. Human Brain Mapping, 2022, 43, 1821-1835.	1.9	7
10	A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics. Acta Neuropathologica Communications, 2022, 10, 20.	2.4	5
11	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
12	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
13	Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature, 2022, 605, 310-314.	13.7	88
14	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	1.8	1
15	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
16	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	5.8	34
17	Development of a sensitive trial-ready poly(GP) CSF biomarker assay forC9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	0.9	12
18	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700

#	Article	IF	Citations
19	Underlying genetic variation in familial frontotemporal dementia: sequencing of 198 patients. Neurobiology of Aging, 2021, 97, 148.e9-148.e16.	1.5	17
20	Emotion recognition of morphed facial expressions in presymptomatic and symptomatic frontotemporal dementia, and Alzheimerâ€™s dementia. Journal of Neurology, 2021, 268, 102-113.	1.8	15
21	Fluid biomarkers in frontotemporal dementia: past, present and future. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 204-215.	0.9	62
22	Brain volumetric deficits in MAPT mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	1.7	21
23	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36
24	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.4	31
25	Unfolded protein response activation in C9orf72 frontotemporal dementia is associated with dipeptide pathology and granulovacuolar degeneration in granule cells. Brain Pathology, 2021, 31, 163-173.	2.1	18
26	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimerâ€™s disease. NeuroImage: Clinical, 2021, 31, 102712.	1.4	42
27	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
28	Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 494-501.	0.9	27
29	Distinctive pattern of temporal atrophy in patients with frontotemporal dementia and the I383V variant in TARDBP. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 787-789.	0.9	5
30	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	0.9	10
31	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. Neurobiology of Aging, 2021, 103, 158.e1-158.e5.	1.5	8
32	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
33	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	0.9	17
34	Novel TUBA4A Variant Associated With Familial Frontotemporal Dementia. Neurology: Genetics, 2021, 7, e596.	0.9	18
35	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
36	[¹⁸ F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. Neurology, 2021, 97, e1017-e1030.	1.5	16

#	Article	IF	Citations
37	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	3.0	12
38	Molecular Pathways Involved in Frontotemporal Lobar Degeneration with TDP-43 Proteinopathy: What Can We Learn from Proteomics?. International Journal of Molecular Sciences, 2021, 22, 10298.	1.8	12
39	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	2.8	18
40	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	1.5	3
41	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. Translational Psychiatry, 2021, 11, 451.	2.4	6
42	Fluid Biomarkers of Frontotemporal Lobar Degeneration. Advances in Experimental Medicine and Biology, 2021, 1281, 123-139.	0.8	7
43	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28
44	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	1.4	8
45	Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 502-509.	0.9	28
46	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	2.2	13
47	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811.	3.7	7
48	Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies. Biomolecules, 2021, 11, 1484.	1.8	3
49	In vivo PET imaging of neuroinflammation in familial frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 231-231.	0.9	3
50	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9
51	Neuroanatomy of FTD: Wholeâ€brain correlations between symptoms and pathologies. Alzheimer's and Dementia, 2021, 17, e056016.	0.4	0
52	Pattern of progression in MAPTâ€related frontotemporal dementia: Results from the GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
53	Detecting clinical progression from abnormal regional brain volumes at baseline in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
54	A dataâ€driven disease progression model of fluid biomarkers in genetic FTD. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
55	Atrophy patterns in sporadic and genetic behavioral variant frontotemporal dementia reflect brain network architecture. Alzheimer's and Dementia, 2021, 17, .	0.4	0
56	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
57	From brain volumes to subgroup classification in genetic mutation carriers for frontotemporal dementia: A cluster analysis in the GENFI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
58	Proteomics of the dentate gyrus reveals semantic-dementia-specific biology.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e052092.	0.4	0
59	Mapping tau burden and neuronal loss in MAPT-associated frontotemporal lobar degeneration.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e054141.	0.4	0
60	Genetic screening in early-onset Alzheimer's disease identified three novel presenilin mutations. Neurobiology of Aging, 2020, 86, 201.e9-201.e14.	1.5	16
61	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	2.2	37
62	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
63	Family History is Associated with Phenotype in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2020, 73, 269-275.	1.2	2
64	SomaticTARDBPvariants as a cause of semantic dementia. Brain, 2020, 143, 3827-3841.	3.7	12
65	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	0.9	25
66	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	0.9	12
67	Classification using fractional anisotropy predicts conversion in genetic frontotemporal dementia, a proof of concept. Brain Communications, 2020, 2, fcaa079.	1.5	3
68	Clinical Conditions â€œSuggestive of Progressive Supranuclear Palsyâ€â€”Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313.	2.2	22
69	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	1.5	20
70	Dissecting frontotemporal dementia: Correlations between neuropsychiatric symptoms and neuropathology. Alzheimer's and Dementia, 2020, 16, e038926.	0.4	0
71	Exome sequencing identifies three novel ADâ€associated genes. Alzheimer's and Dementia, 2020, 16, e041592.	0.4	6
72	Trajectory of apathy, cognition and neural correlates in the decades before symptoms in frontotemporal dementia. Alzheimer's and Dementia, 2020, 16, e041821.	0.4	0

#	Article	IF	Citations
73	SORL1 â€variant carriers in ADESâ€ADSP: A higher level of variant pathogenicity associates with earlier age at onset of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044492.	0.4	1
74	Heterogeneous distribution of pathology in behavioral variant Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e044830.	0.4	1
75	The Free Cued Selective Reminding Test detects episodic memory impairment in the presymptomatic period of familial frontotemporal dementia within the GENFI cohort. Alzheimer's and Dementia, 2020, 16, e045768.	0.4	0
76	Assessment of cortical vulnerability of the anterior cingulate cortex in the behavioral variant of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045770.	0.4	0
77	CSF biomarkers for frontotemporal dementia and its pathological subtypes. Alzheimer's and Dementia, 2020, 16, e045851.	0.4	0
78	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	3.9	210
79	Clinical and pathologic phenotype of a large family with heterozygous STUB1 mutation. Neurology: Genetics, 2020, 6, e417.	0.9	19
80	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	0.9	33
81	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020, 143, 1632-1650.	3.7	158
82	Copathology in Progressive Supranuclear Palsy: Does It Matter?. Movement Disorders, 2020, 35, 984-993.	2.2	48
83	Clinical and Pathological Phenotypes of LRP10 Variant Carriers with Dementia. Journal of Alzheimer's Disease, 2020, 76, 1161-1170.	1.2	7
84	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
85	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	0.9	55
86	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	2.8	19
87	Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology. Annals of Neurology, 2020, 87, 950-961.	2.8	30
88	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	1.1	26
89	LRP10 variants in progressive supranuclear palsy. Neurobiology of Aging, 2020, 94, 311.e5-311.e10.	1.5	6
90	EIF2AK3 variants in Dutch patients with Alzheimer's disease. Neurobiology of Aging, 2019, 73, 229.e11-229.e18.	1.5	25

#	Article	IF	Citations
91	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	4.9	128
92	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	2.1	33
93	A multimodal MRI-based classification signature emerges just prior to symptom onset in frontotemporal dementia mutation carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1207-1214.	0.9	18
94	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
95	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	0.9	19
96	LRP10 variants in Parkinson's disease and dementia with Lewy bodies in the South-West of the Netherlands. Parkinsonism and Related Disorders, 2019, 65, 243-247.	1.1	14
97	Education modulates brain maintenance in presymptomatic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1124-1130.	0.9	23
98	Novel <scp>CSF</scp> biomarkers in genetic frontotemporal dementia identified by proteomics. Annals of Clinical and Translational Neurology, 2019, 6, 698-707.	1.7	42
99	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	2.2	93
100	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	3.7	41
101	Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a longitudinal MRI study. Neurobiology of Aging, 2019, 76, 115-124.	1.5	59
102	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
103	Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. Neurology, 2019, 93, e1699-e1706.	1.5	19
104	O4â€02â€01: PHASE 2A RANDOMIZED, DOUBLEâ€BLIND, PLACEBOâ€CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRMâ€0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS. Alzheimer's and Dementia, 2019, 15, P1231.	0.4	4
105	ICâ€Pâ€097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING. Alzheimer's and Dementia, 2019, 15, P84.	0.4	0
106	Multimodal MRI of grey matter, white matter, and functional connectivity in cognitively healthy mutation carriers at risk for frontotemporal dementia and Alzheimer's disease. BMC Neurology, 2019, 19, 343.	0.8	10
107	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
108	Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. Brain, 2019, 142, 193-208.	3.7	73

#	Article	IF	Citations
109	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	2.1	16
110	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	1.5	47
111	Hippocampal transcriptome profiling combined with protein-protein interaction analysis elucidates Alzheimer's disease pathways and genes. Neurobiology of Aging, 2019, 74, 225-233.	1.5	30
112	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology, 2018, 90, e1231-e1239.	1.5	94
113	Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Annals of Clinical and Translational Neurology, 2018, 5, 583-597.	1.7	48
114	Single Subject Classification of Alzheimerâ€™s Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. Journal of Alzheimer's Disease, 2018, 62, 1827-1839.	1.2	33
115	Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia. Journal of Neurology, 2018, 265, 1381-1392.	1.8	49
116	The Effect of Predictive Testing in Adultâ€Onset Neurodegenerative Diseases on Social and Personal Life. Journal of Genetic Counseling, 2018, 27, 947-954.	0.9	10
117	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
118	Meta-analytic Review of Memory Impairment in Behavioral Variant Frontotemporal Dementia. Journal of the International Neuropsychological Society, 2018, 24, 593-605.	1.2	26
119	Comparison of arterial spin labeling registration strategies in the multiâ€center GENetic frontotemporal dementia initiative (GENFI). Journal of Magnetic Resonance Imaging, 2018, 47, 131-140.	1.9	41
120	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	1.5	151
121	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	1.5	40
122	P1â€433: GRAY MATTER DEFICITS IN SYMPTOMATIC AND PRESYMPTOMATIC MAPT MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P475.	0.4	0
123	O3â€13â€01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1054.	0.4	0
124	P2â€153: DIFFERENT CORTICAL NEURONAL VULNERABILITY IN DEMENTIA WITH AND WITHOUT PREDOMINANT BEHAVIOURAL SYMPTOMS. Alzheimer's and Dementia, 2018, 14, P726.	0.4	0
125	P3â€201: UNFOLDED PROTEIN RESPONSE ACTIVATION IN C9ORF72 FRONTOTEMPORAL DEMENTIA CASES. Alzheimer's and Dementia, 2018, 14, P1145.	0.4	0
126	ICâ€Pâ€110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P94.	0.4	0

#	Article	IF	Citations
127	P2â€291: THE DIAGNOSTIC CHALLENGE OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER'S DISEASE: A CASE REPORT. Alzheimer's and Dementia, 2018, 14, P792.	0.4	0
128	Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimerâ€™s Disease: A Case Report. Journal of Alzheimer's Disease, 2018, 66, 1363-1369.	1.2	5
129	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
130	Prevalence of amyloidâ€Î²2 pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
131	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	5.8	263
132	Colony-Stimulating Factor 1 Receptor (CSF1R) Regulates Microglia Density and Distribution, but Not Microglia Differentiation InÂVivo. Cell Reports, 2018, 24, 1203-1217.e6.	2.9	110
133	Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1. Nature Communications, 2018, 9, 2929.	5.8	20
134	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	3.0	34
135	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	1.7	39
136	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. Journal of Alzheimer's Disease, 2018, 65, 1-16.	1.2	28
137	Single-subject classification of presymptomatic frontotemporal dementia mutation carriers using multimodal MRI. NeuroImage: Clinical, 2018, 20, 188-196.	1.4	15
138	Three VCP Mutations in Patients with Frontotemporal Dementia. Journal of Alzheimer's Disease, 2018, 65, 1139-1146.	1.2	19
139	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2018, 17, 597-608.	4.9	101
140	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
141	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	3.7	55
142	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
143	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimerâ€™s Disease in a Family with Several Generations of APOE-É›4 Homozygosity. Journal of Alzheimer's Disease, 2017, 56, 63-74.	1.2	32
144	Imaging and fluid biomarkers in frontotemporal dementia. Nature Reviews Neurology, 2017, 13, 406-419.	4.9	163

#	Article	IF	Citations
145	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	1.4	63
146	Characterization of pathogenic SORL1 genetic variants for association with Alzheimerâ€™s disease: a clinical interpretation strategy. European Journal of Human Genetics, 2017, 25, 973-981.	1.4	102
147	Multireceptor fingerprints in progressive supranuclear palsy. Alzheimer's Research and Therapy, 2017, 9, 28.	3.0	3
148	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	179
149	Multiparametric computer-aided differential diagnosis of Alzheimerâ€™s disease and frontotemporal dementia using structural and advanced MRI. European Radiology, 2017, 27, 3372-3382.	2.3	64
150	[ICâ€Pâ€130]: MRIâ€BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY. Alzheimer's and Dementia, 2017, 13, P98.	0.4	0
151	Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology, 2017, 89, 1256-1264.	1.5	82
152	An update on the genetics of dementia with Lewy bodies. Parkinsonism and Related Disorders, 2017, 43, 1-8.	1.1	31
153	[P4â€“146]: NEUROFILAMENT LIGHT CHAIN AND PHOSPHOTAU/TAU RATIO AS CSF BIOMARKERS IN FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1313.	0.4	0
154	Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain, 2017, 140, aww339.	3.7	153
155	A novel CCM2 variant in a family with nonâ€progressive cognitive complaints and cerebral microbleeds. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 220-226.	1.1	6
156	[P1â€“029]: IN GENETIC FRONTOTEMPORAL DEMENTIA, FUNCTIONAL NETWORK EFFICIENCY IS MAINTAINED UNTIL THE ONSET OF SYMPTOMS: EVIDENCE FOR FUNCTIONAL RESILIENCE TO STRUCTURAL CHANGE. Alzheimer's and Dementia, 2017, 13, P244.	0.4	0
157	[ICâ€03â€“04]: WHITE MATTER HYPERINTENSITIES IN GENETIC FRONTOTEMPORAL DEMENTIA: A GENFI STUDY. Alzheimer's and Dementia, 2017, 13, P9.	0.4	0
158	[P1â€“415]: IN GENETIC FRONTOTEMPORAL DEMENTIA, FUNCTIONAL NETWORK EFFICIENCY IS MAINTAINED UNTIL THE ONSET OF SYMPTOMS: EVIDENCE FOR FUNCTIONAL RESILIENCE TO STRUCTURAL CHANGE. Alzheimer's and Dementia, 2017, 13, P436.	0.4	0
159	[P1â€“437]: PRESYMPTOMATIC WHITE MATTER INTEGRITY LOSS IN FAMILIAL FRONTOTEMPORAL DEMENTIA IN THE GENETIC FRONTOTEMPORAL DEMENTIA INITIATIVE (GENFI) COHORT: A MULTIâ€CENTRE, CROSSâ€SECTIONAL DIFFUSION TENSOR IMAGING STUDY. Alzheimer's and Dementia, 2017, 13, P449.	0.4	1
160	[P2â€“338]: ARE NEUROFILAMENT LIGHT CHAIN AND WHITE MATTER INTEGRITY RELATED BIOMARKERS FOR FAMILIAL FRONTOTEMPORAL DEMENTIA?. Alzheimer's and Dementia, 2017, 13, P751.	0.4	1
161	Combining multiple anatomical MRI measures improves Alzheimer's disease classification. Human Brain Mapping, 2016, 37, 1920-1929.	1.9	53
162	¹⁸F-AV-1451 tau PET imaging correlates strongly with tau neuropathology inMAPTmutation carriers. Brain, 2016, 139, 2372-2379.	3.7	149

#	Article	IF	Citations
163	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.	1.2	35
164	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 521-537.	1.2	48
165	P1â€123: Differential Expression in Hippocampus of Alzheimer's Disease Patients. Alzheimer's and Dementia, 2016, 12, P451.	0.4	0
166	ICâ€Pâ€079: Neuropsychological and Gray Matter Volume Decline in Presymptomatic C9ORF72 Mutation Carriers. Alzheimer's and Dementia, 2016, 12, P62.	0.4	1
167	P3â€317: Neuropsychological Profiles in Autosomal Dominant Hereditary Frontotemporal Dementia Due to Mapt, GNR or C9ORF72 Mutations. Alzheimer's and Dementia, 2016, 12, P965.	0.4	0
168	O3â€09â€04: PRESYMPTOMATIC COGNITIVE DECLINE IN FAMILIAL FRONTOTEMPORAL DEMENTIA: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2016, 12, P308.	0.4	0
169	O4-02-06: Neuropsychological and Gray Matter Volume Decline in Presymptomatic C9ORF72 Mutation Carriers. , 2016, 12, P336-P337.		0
170	Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study. NeuroImage: Clinical, 2016, 12, 460-465.	1.4	46
171	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	1.7	207
172	Presymptomatic cognitive decline in familial frontotemporal dementia. Neurology, 2016, 87, 384-391.	1.5	42
173	Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 330-340.	0.6	63
174	Defining the spectrum of frontotemporal dementias associated with TARDBP mutations. Neurology: Genetics, 2016, 2, e80.	0.9	56
175	microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP). Neurogenetics, 2016, 17, 165-171.	0.7	20
176	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	1.5	37
177	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. Human Brain Mapping, 2016, 37, 978-988.	1.9	48
178	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology, 2016, 279, 838-848.	3.6	79
179	Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 86-94.	1.2	68
180	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2016, 38, 21-31.	1.5	40

#	Article	IF	Citations
181	IC-P-054: Grey matter differences in genetic frontotemporal dementia: Results from the genfi study. , 2015, 11, P42-P42.		0
182	Reply: PRKAR1B mutations are a rare cause of FUS negative neuronal intermediate filament inclusion disease. Brain, 2015, 138, e358-e358.	3.7	0
183	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. NeuroImage: Clinical, 2015, 9, 418-429.	1.4	38
184	P2-024: Whole-exome sequencing in dutch families with Alzheimer's disease. , 2015, 11, P490-P490.		0
185	O2-01-01: Grey matter differences in genetic frontotemporal dementia: Results from the genfi study. , 2015, 11, P171-P171.		0
186	O2-01-02: Longitudinal, structural and functional connectivity in presymptomatic familial frontotemporal dementia. , 2015, 11, P171-P172.		0
187	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1605.e13-1605.e20.	1.5	27
188	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. NeuroImage, 2015, 111, 562-579.	2.1	266
189	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	4.9	432
190	PLD3 variants in population studies. Nature, 2015, 520, E2-E3.	13.7	49
191	The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results. BMC Neurology, 2014, 14, 254.	0.8	57
192	Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology, 2014, 83, e19-26.	1.5	127
193	Diagnostic classification of arterial spin labeling and structural MRI in presenile early stage dementia. Human Brain Mapping, 2014, 35, 4916-4931.	1.9	80
194	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
195	No mutations in hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral sclerosis, frontotemporal dementia, and inclusion body myopathy. Neurobiology of Aging, 2014, 35, 1956.e9-1956.e11.	1.5	26
196	P4-278: IDENTIFICATION OF NOVEL DIAGNOSTIC CSF PROTEIN BIOMARKERS FOR FTD WITH HIGH DISCRIMINATORY POWER. , 2014, 10, P886-P886.		0
197	O2-14-01: HETEROGENEOUS LANGUAGE PROFILES IN PATIENTS WITH PRIMARY PROGRESSIVE APHASIA DUE TO ALZHEIMER'S DISEASE. , 2014, 10, P196-P197.		0
198	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	4.9	1,039

#	Article	IF	Citations
199	Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 476-486.	0.9	508
200	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
201	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	3.8	3,833
202	Symmetrical Corticobasal Syndrome Caused by a Novel c.314dup Progranulin Mutation. Journal of Molecular Neuroscience, 2011, 45, 354-358.	1.1	32
203	Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. Journal of Neurology, 2010, 257, 747-753.	1.8	131
204	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	9.4	479
205	Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurology, The, 2008, 7, 965-974.	4.9	203
206	Epidemiological aspects of frontotemporal dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 331-341.	1.0	5
207	The Î”K280 Mutation in MAP tau Favors Exon 10 Skipping In Vivo. Journal of Neuropathology and Experimental Neurology, 2007, 66, 17-25.	0.9	50
208	Hereditary Frontotemporal Dementia Caused by Tau Gene Mutations. Brain Pathology, 2007, 17, 63-73.	2.1	182
209	Phenotypic Variation in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17. Dementia and Geriatric Cognitive Disorders, 2004, 17, 261-264.	0.7	21
210	Variable phenotypic expression and extensive tau pathology in two families with the noveltau mutation L315R. Annals of Neurology, 2003, 54, 573-581.	2.8	82
211	A Mutation in the Fibroblast Growth Factor 14 Gene Is Associated with Autosomal Dominant Cerebral Ataxia. American Journal of Human Genetics, 2003, 72, 191-199.	2.6	255
212	Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. Human Molecular Genetics, 2000, 9, 3075-3082.	1.4	57
213	Association of missense and 5â€²-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393, 702-705.	13.7	3,333